Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc. (RVMD)
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. As data from the first-in-human clinical study of RMC-6236 continue to mature, the company is preparing to advance RMC-6236 into randomized, controlled, monotherapy pivotal trials. The first trial expected to launch will evaluate RMC-6236 in the second line (2L) treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC), followed by the expected launch of a second trial to evaluate RMC-6236 in the 2L treatment of patients with advanced non-small cell lung cancer (NSCLC).Expanding the
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $44.00 price target on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its price target raised by analysts at Wedbush from $42.00 to $46.00. They now have an "outperform" rating on the stock.MarketBeat
- Revolution Medicines, Inc. (NASDAQ: RVMD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $46.00 price target on the stock.MarketBeat
- Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress [Yahoo! Finance]Yahoo! Finance
RVMD
Earnings
- 5/8/24 - Beat
RVMD
Sec Filings
- 5/22/24 - Form 4
- 5/21/24 - Form 144
- 5/8/24 - Form S-3ASR
- RVMD's page on the SEC website